Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.10.24.761513

Can Folding Models Tell Binders from Bluffers? Evidence from POISK: The Patent-Derived Antibody Dataset

Abstract

Structure prediction models are increasingly deployed as zero-shot digital screens in antibody design, operating under the assumption that high folding confidence implies true binding. However, rigorous validation of this premise has been limited by small test sets, narrow target diversity, and the risk of data leakage from training-adjacent structures. Here we introduce POISK: Patent-extracted Organization of Immunoglobulin Sequence Knowledge, a large-scale dataset derived from the US patent literature, comprising 89074 antibody-antigen records extracted from 10110 patents using an LLM-based pipeline. From this resource, we curate a balanced benchmark set of 22494 complexes: 11247 patent-validated binders without a known resolved structure paired with putative non-binders constructed from sequence-similar human repertoire antibodies. Using this dataset, we benchmark six leading structure prediction models (AlphaFold-Multimer, Boltz-2, IntelliFold v2, OpenFold3, Protenix-v1, and Protenix-v2) on their ability to discriminate binders from decoys. The best-performing model, Protenix-v2, achieves 72% pairwise accuracy over all pairs and 87% on the most confident half of predictions, and correctly identifies the true binder from a pool of 50 candidates in 29% of trials; this represents a substantial enrichment over random selection, yet remains far from reliable single-candidate identification. Structural consensus across models also discriminates binders from decoys, with pairwise accuracy reaching 73.1% when three or more models converge on a pose (DockQ>0.23, covering around 54.2% of pairs). Epitope localization remains unreliable: the best model contacts annotated epitope residues in only 62.8% of cases, indicating that binding discrimination does not establish accurate epitope localization. Our results suggest that current folding models provide useful but limited signal for antibody screening and should be complemented by orthogonal methods. We release POISK as a community resource for future benchmarking and model training.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tupikina, D., Roncoli, A., Bujotzek, A., Abanades, B.. 2026-10-26. Can Folding Models Tell Binders from Bluffers? Evidence from POISK: The Patent-Derived Antibody Dataset. https://doi.org/10.64898/2026.10.24.761513

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Carrier-Limited Release Risk in Electrospun Nanofibers for Regenerative Endodontics: Constraint Discovery from 25 Formulations

Regenerative endodontics needs an intracanal carrier that keeps disinfecting across a dressing interval that clinicians schedule at one to four weeks, without harming the stem cells that rebuild the pulp. We ask what one completed 25-formulation electrospinning campaign of poly(vinylpyrrolidone) (PVP) fibers carrying metronidazole, ciprofloxacin, minocycline and Ca(OH)2 can decide, and use machine learning for constraint discovery and decision support rather than as a new predictor. After an audit against the source thesis, logistic regression predicts fine-fiber formation at 96% leave-one-out accuracy, but a one-threshold rule does as well, the gain over the 80% majority baseline is not significant (exact McNemar p = 0.125), and accuracy falls to 84% when mixture loading is encoded per component. Diameter models interpolate within formulation families (ridge MAE 193 nm, 95% CI 96 to 317 nm) and fail across them (R^2 < 0). Because the campaign never measured release, we assemble a same-drug, cross-carrier evidence table: 17 bounded metronidazole and ciprofloxacin observations from seven studies, with two-sided censoring. Water-soluble carriers (PVP, PVA) completed release within 80 h (PVP within 8 h); no water-insoluble monolithic carrier reached 90% within its observation window, releasing 1.5 to 50%; both within-study comparisons separate at matched loading; and blend, core-shell and thick-mat architectures released over 3 to 28 days. The PVP mats therefore carry a carrier-limited release risk, not a proven ceiling, and one dissolution experiment can confirm or overturn it. A censoring-aware screen keeps three necessarily and one possibly nondominated formulation, and fixed-budget replays show that uncertainty sampling finds failed formulations sooner, except the one it is confidently wrong about.

bioinformatics↗

CellMethMarker provides an integrated database of human cell- and tissue-type-specific DNA methylation markers

Cell- and tissue-type-specific DNA methylation markers provide epigenetic signatures of cellular identity and are widely used to infer cellular origin from bulk and single-cell methylomes. Existing resources mainly emphasize disease-associated biomarkers, methylome atlases, genomic annotations or RNA-based cell markers, leaving an unmet need for an integrated region-level resource dedicated to such markers. Here we present CellMethMarker (http://gu-zhanglab.hfcas.ac.cn/CellMethMarker), a curated database integrating 347,514 de novo markers derived from uniformly processed whole-genome and reduced-representation bisulfite sequencing datasets, 2,203,507 literature-derived marker records and harmonized metadata for 2,810 samples. CellMethMarker enables cell- and tissue-centered marker retrieval, coordinate-based search, genome-browser visualization, interactive methylation analysis and data download. In an independent single-cell methylome atlas, these markers recover the expected cell-type-associated methylation patterns, and a platform-matched reference built from them lowers the mean deconvolution error from 0.365 to 0.144. CellMethMarker therefore links region-level DNA methylation variation to cellular identity and supports methylome-based cell-type annotation and deconvolution.

bioinformatics↗

IG-28 enables identification and quantification of high-confidence isoforms from large bulk and single-cell full-length cDNA datasets

The technology to sequence full-length transcriptomes from bulk and single-cell samples has rapidly advanced. As a result, full-length cDNA datasets now reach billions of reads in size which is beyond the capability of most established isoform identification tools. Here, we introduce IG-28 which addresses this challenge with its capability to process and analyze large fl-cDNA datasets fast and using minimal computational resources. In contrast to its predecessor Mandalorion, IG-28 is not limited to bulk fl-cDNA but is capable of parsing, processing, and analyzing single-cell fl-cDNA datasets. It does so in a lightweight, flexible manner, integrating seamlessly with established scRNA-seq analysis workflows. We benchmarked IG-28 against a variety of established and new isoform identification tools using several bulk and a complex single-cell fl-cDNA dataset and found that IG-28 consistently outperformed the other tools by identifying high-confidence public isoforms.

bioinformatics↗